Barinthus Biotherapeutics (STU:2AB) Tariff Resilience Score: 4/10 (As of Jul. 01, 2026)


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.57
GF Value €0.96
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Tariff Resilience Score?

Barinthus Biotherapeutics STU:2AB -0.88% 14 Tariff Resilience Score is 4 as of Jul. 01, 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.96. The stock has 1 warning sign investors should review. Among 1,374 Biotechnology companies, Barinthus Biotherapeutics ranks better than 52.33% on this metric.

Barinthus Biotherapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Barinthus Biotherapeutics has Barinthus Biotherapeutics relies on global supply chains for raw materials, making it vulnerable to tariffs. The biotech industry has limited exemptions, and previous tariffs have affected costs. The company is exploring alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Barinthus Biotherapeutics might have Average Resilient.

Barinthus Biotherapeutics  (STU:2AB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Barinthus Biotherapeutics Tariff Resilience Score Related Terms

STU:2AB vs VTGN, PSTV, PVCT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Tariff Resilience Score falls into.


STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Barinthus Biotherapeutics (STU:2AB) has a Tariff Resilience Score of 4 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Barinthus Biotherapeutics ranks #655 out of 1374 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Barinthus Biotherapeutics' Tariff Resilience Score too high?
Barinthus Biotherapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Barinthus Biotherapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #655 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Tariff Resilience Score compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #655 out of 1374 companies for Tariff Resilience Score. This puts Barinthus Biotherapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Barinthus Biotherapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Tariff Resilience Score of 4. The stock's GF Value™ is €0.96, compared to a current price of €0.57 — trading 41.1% below its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Tariff Resilience Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.57 is trading 41.1% below its estimated GF Value™ of €0.96.

Key valuation signals for STU:2AB:

  • Tariff Resilience Score: 4
  • GF Value™: €0.96 vs. price of €0.57 (41.1% below fair value)
  • GF Score™: 14/100 with 1 warning sign
  • Industry Position: 0% at the Biotechnology median (#655 of 1374)

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.96
GF Value